|
|
IEC Webcasts Available
Webcasts of IEC symposia on "Management of AD Patients on Systemic Treatments during COVID-19" is now available on-demand.
|
|
NEA Presents Eczema Expo 2020
The National Eczema Association will be holding its Eczema Expo 2020 virtually this year.
For further details, see https://nationaleczema.org/eczema-expo/ |
Coronavirus SECURE-AD Registry
SECURE-AD (Surveillance Epidemiology of Corona Virus (COVID-19) Under Research Exclusion – Atopic Dermatitis; www.covidderm.org) is a secure, online, de-identified international reporting registry for health care providers to report outcomes of COVID-19 in AD patients who have been Covid-19 infected or where such an infection has been strongly suspected.
|
IEC Statement on COVID 19
IEC would like to provide guidance on the use of systemic treatments for atopic dermatitis (AD; commonly called eczema) in the context of the COVID-19 pandemic, based on currently available pandemic and pharmacologic information.
|
IEC Introduces New Educational Modules for Clinical Investigators
The International Eczema Council is providing two new educational modules for atopic dermatitis (AD) clinical investigators.
|
Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) Scale Now Available
Eli Lilly and Company (Lilly) has worked with numerous atopic dermatitis experts, including International Eczema Council advisors and Industry experts, to develop the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) scale for use in clinical trials.
|
|
|
|
|
